Skip to main content UVA Health logo of UVA Health
Newsroom
July 13, 2021

Findings to Help Prevent, Treat Dangerous Atrial Fibrillation

A stethoscope on an ECG.

New research will help doctors identify, treat and prevent potentially dangerous irregular heartbeats in patients with hypertrophic cardiomyopathy (HCM), a common heart condition in which the heart thickens and strains to pump blood.

These chaotic heart rhythms are known as atrial fibrillation. Atrial fibrillation can be asymptomatic, but it can lead to blood clots, stroke or even heart failure. The new research, from an international team of doctors and scientists, identifies risk factors for major atrial fibrillation outcomes, such as the need for procedures or hospitalization for more than 24 hours, in patients with hypertrophic cardiomyopathy.

Age was the dominant predictor, the researchers found. But they also identified a list of other predictors, including obesity as measured by Body Mass Index (BMI). Obesity was particularly important in younger patients, the researchers conclude.

“The latter finding points out the importance of weight loss and exercise in HCM patients,” said researcher Christopher Kramer, MD, the chief of the Division of Cardiovascular Medicine at UVA Health, Virginia’s only designated Center of Excellence by the Hypertrophic Cardiomyopathy Association. “Until only recently, exercise was thought to be contraindicated in HCM. This is no longer the case based on recent studies.”

Atrial Fibrillation in Hypertrophic Cardiomyopathy

Like atrial fibrillation, hypertrophic cardiomyopathy often goes undiagnosed. It is, however, the most common inheritable heart disease, and it is the most common cause of sudden cardiac death in young athletes.

Atrial fibrillation is a common complication among patients with hypertrophic cardiomyopathy. Previous studies have focused on detecting atrial fibrillation, as patients may require blood thinners to prevent stroke. But Kramer and his colleagues wanted to look at atrial fibrillation outcomes to better identify those who need early or tailored interventions.

The researchers examined data from 2,631 patients, identifying 127 major end- points, such as needing hospitalization or catheter ablation, in 96 of the patients. Key risk factors for reaching an endpoint included age; BMI; size and function of the heart’s left atrium; moderate or severe failure of the heart’s mitral valve to close completely; and history of arrhythmia (irregular heartbeat).

Obesity was a stronger risk factor in younger patients than older ones. The remaining risk factors were greater risk factors for middle-aged and older patients.

The researchers say their findings can be used to create a risk-assessment tool for patients, to identify those at risk and help keep them out of the hospital.

“These findings will help physicians who treat HCM patients, as they can target the risk factors that lead to atrial fibrillation,” Kramer said.

Findings Published

The researchers have published their findings in the scientific journal JACC: Clinical Electrophysiology. The research team consisted of Kramer, John P. DiMarco, Paul Kolm, Carolyn Y. Ho, Milind Y. Desai, Raymond Y. Kwong, Sarahfaye F. Dolman, Nancy Geller, Dong-Yun Kim, Martin S. Maron, Evan Appelbaum, Michael Jerosch-Herold, Matthias G. Friedrich, Jeanette Schulz-Menger, Stefan K. Piechnik, Masliza Mahmod, Daniel Jacoby, James White, Amedeo Chiribiri, Adam Helms, Lubna Choudhury, Michelle Michels, William Bradlow, Michael Salerno, Dana K. Dawson, Jonathan W. Weinsaft, Colin Berry, Sherif F. Nagueh, Chiara Buccarelli-Ducci, Barbara Casadei, Hugh Watkins, William S. Weintraub and Stefan Neubauer.

The research was supported by the National Institutes of Health; the National Heart, Lung and Blood Institute (grant U01HL117006-01A1); and the Oxford NIHR Biomedical Research Centre. Kramer has received research funding from BMS and Cytokinetics and has been consultant for BMS and Cytokinetics. A full list of the authors’ disclosures is included in the paper.

To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog.

MORE: Results in from the most comprehensive study of hypertrophic cardiomyopathy ever undertaken.

Categories: All Releases

Media Contact
Joshua Barney

Deputy Public Information Officer

Email  |  jdb9a@virginia.edu

Phone  |  434.906.8864

Latest News